Avalo Therapeutics (AVTX) Non-Current Assets (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Non-Current Assets came in at $11.1 million in Q1 2026, down 4.51% YoY from $11.6 million in Q1 2025, and down 1.0% on a QoQ basis from $11.2 million in Q4 2025.
Avalo Therapeutics (AVTX) Non-Current Assets (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Non-Current Assets data on file, last reported at $11.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 4.51% year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.9 million (down 6.77% YoY) and the FY2025 annual result came in at $11.2 million, down 5.66% from the prior year.
- Non-Current Assets declined to $11.1 million in Q1 2026, from $11.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $18.2 million in Q1 2022 to a low of $11.1 million in Q1 2026.
- A 5-year average of $14.0 million and a median of $12.5 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets grew 5.75% — and 2024, when it decreased 26.3%.
- Tracing AVTX's Non-Current Assets over 5 years: stood at $17.0 million in 2022, then decreased by 25.68% to $12.6 million in 2023, then fell by 6.0% to $11.8 million in 2024, then slipped by 5.66% to $11.2 million in 2025, then declined by 1.0% to $11.1 million in 2026.
- The last three Non-Current Assets figures came in at $11.1 million (Q1 2026), $11.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 82.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.85 Mn |
| Mar 31, 2026 | 11.06 Mn |
| Dec 31, 2025 | 11.17 Mn |
| Sep 30, 2025 | 11.25 Mn |
| Jun 30, 2025 | 11.40 Mn |
| Mar 31, 2025 | 11.58 Mn |
| Dec 31, 2024 | 11.84 Mn |
| Sep 30, 2024 | 12.31 Mn |
| Jun 30, 2024 | 12.41 Mn |
| Mar 31, 2024 | 12.52 Mn |
| Dec 31, 2023 | 12.60 Mn |
| Sep 30, 2023 | 16.61 Mn |
| Jun 30, 2023 | 16.72 Mn |
| Mar 31, 2023 | 16.98 Mn |
| Dec 31, 2022 | 16.95 Mn |
| Sep 30, 2022 | 17.10 Mn |
| Jun 30, 2022 | 17.20 Mn |
| Mar 31, 2022 | 18.24 Mn |
| Dec 31, 2021 | 18.37 Mn |
| Sep 30, 2021 | 18.35 Mn |